Cardiovascular Disease Doctors in Prestonsburg, KY Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Dr. Himachala R. Veligandla, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5000 Ky Route 321, Prestonsburg, KY 41653 Phone: 606-889-6210    Fax: 606-889-6291

Dr. Gary Frank Roberts, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1279 Old Abbott Mountain Rd, Prestonsburg, KY 41653 Phone: 606-886-0892    Fax: 606-886-9746

Joel David Talley Iii, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5000 Ky Route 321, Prestonsburg, KY 41653 Phone: 606-886-7645

News Archive

New 'platform' for processing dietary fat discovered

A new "platform" with a crucial role in the body's ability to process and take up fat from the diet has been found, according to a report in the April issue of the journal Cell Metabolism, published by Cell Press.

Survival of mesothelioma patients is improving, new data reveals

Mesothelioma is a rare, aggressive type of cancer with no cure. However, the latest data from the Australian Institute of Health and Welfare suggests survival is improving.

HPM recognizes 19 Michigan health care providers for outstanding quality, service

The 19 Michigan health care providers were identified as the top primary care offices through a rigorous selection process that was based on Health Plan of Michigan's 2009 quality incentive plan. "We wanted to show our gratitude to our highest ranking health care providers for their excellence in quality and service," said Raymond D. Pitera, Vice President of Provider Service for Health Plan of Michigan. "We truly appreciate the access to quality services they provide to our Medicaid Members."

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.

Read more Medical News

› Verified 5 days ago